口服马替洛尔或普萘洛尔治疗婴幼儿血管瘤403例临床分析

Sanamed Pub Date : 2023-01-01 DOI:10.5937/sanamed0-46005
Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek
{"title":"口服马替洛尔或普萘洛尔治疗婴幼儿血管瘤403例临床分析","authors":"Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek","doi":"10.5937/sanamed0-46005","DOIUrl":null,"url":null,"abstract":"Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.","PeriodicalId":53269,"journal":{"name":"Sanamed","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients\",\"authors\":\"Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek\",\"doi\":\"10.5937/sanamed0-46005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.\",\"PeriodicalId\":53269,\"journal\":{\"name\":\"Sanamed\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sanamed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/sanamed0-46005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sanamed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/sanamed0-46005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:婴幼儿血管瘤是婴幼儿最常见的良性血管瘤。普萘洛尔(P)是一种非选择性β受体阻滞剂,已成功用于治疗IHs。正在进行的研究调查了局部b-拮抗剂马来酸替马洛尔(TM)在IHs中的疗效。本研究的目的是评估干预措施对儿童血管瘤的治疗效果。材料和方法:我们回顾性分析了2021年3月至2022年3月期间共403例IH患者。将患者分为三组。第一组患者给予TM,剂量为1滴,局部注射,每日2次,0.5%。2组患者给予P,剂量为1 mg/kg,每日2次。第3组患者未接受任何治疗,仅与对照组联系进行观察。结果:中位诊断年龄为5个月(范围0 ~ 60岁),男性占57.1%。32%的患儿接受TM治疗,46.9%的患儿接受P治疗,21.1%的患儿不接受治疗。血管瘤最常见的部位为面部,占39.2%。48例(12%)儿童出现多处血管瘤。患者的中位随访期为4个月(范围0-28)。28.3%的病例血管瘤保持不变,60.3%的病例血管瘤缩小,11.4%的病例血管瘤继续增长。启动TM的主要适应症是浅表血管瘤和小于6个月的婴儿。开始的主要原因P显著高于其他组(P: 0.001)。两组间出血和溃疡发生率无统计学差异(p >0.05)。结论:心得安治疗IH的疗效优于中药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients
Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
23
审稿时长
8 weeks
期刊最新文献
Benefits of breastfeedinig for mother and child Physician burnout levels and associated factors in The Covid-19 pandemic Improvement of medical waste storage procedures Early detection of acute kidney injury in preterm newborns with perinatal asphyxia using serum cystatin Differences between biochemical, hematological, and coagulation parameters among patients with mild and severe COVID-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1